Why Altera Peptides exists
A hormone fragment that loses one effect and retains another is the sort of puzzle that makes a whole subject worth exploring.
An alteration
My curiosity about small biological alterations gave Altera Peptides its starting point. A fragment cut from a hormone, copper bound to a peptide, an enzyme removed from a mouse: each offers a concrete way into a complicated subject.
The KPV study in MC1R-deficient mice is a favourite example. Anti-inflammatory activity persisted after an obvious candidate receptor was impaired. I enjoy KPV's stubborn result in the MC1R-deficient mice. The intellectual reward is the question that becomes sharper afterward.
A claim that an impressive molecular effect establishes broad rejuvenation tests my patience. The human NAD+ precursor review describes how much remains unresolved even where a blood measurement reliably changes. A particular result can be interesting enough on its own terms.
A personal research bulletin
This is a personal research bulletin, about published papers and the biological questions that absorb me. Its scope stops at the experiments and findings; individual medical decisions require a different kind of attention.
Altera Peptides provides no clinical service or product ordering. The bulletin cannot examine readers, choose treatments or arrange access to experimental substances. The site is a place to explore this research, and its pages cannot serve as medical advice about an individual person's care.
The name expresses an interest in alteration. It makes no promise that changing a signal will improve a person's health. Sometimes a modified preparation solves a delivery problem; sometimes the apparently promising biology leaves a much harder clinical question behind.
What could change my mind
I favour KPV work that reaches human trials over another expansive pathway account. For GHK-Cu, a well-described topical formulation with replicated visible benefits would help. For KPV, characterised human exposure and safety would change the conversation before a relief claim could be assessed.
For NAD+, the connection between tissue metabolism and daily function remains especially interesting. Retatrutide already has substantial human weight findings; the questions now extend to durability and longer-term benefit and harm. MC1R's unresolved mechanism fascinates me. A confident answer that has skipped the question has the opposite effect.
Errors and relevant papers are welcome through the corrections mailbox. A useful correction can make a result smaller, larger or more specific. Any of those can improve the account.